A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

NCT02098967 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Myelogenous Leukemia, Acute

Interventions

DRUG: RO6839921
DRUG: RO6839921
DRUG: RO6839921

Sponsor

Hoffmann-La Roche